Cor Medix Inc. CRMD
We take great care to ensure that the data presented and summarized in this overview for CorMedix Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRMD
View all-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.81MShares$20.5 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.72MShares$19.5 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.26MShares$14.3 Million0.05% of portfolio
-
Ubs Group Ag1.09MShares$12.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY844KShares$9.57 Million0.0% of portfolio
Latest Institutional Activity in CRMD
Top Purchases
Top Sells
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Transactions at CRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2026
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
10,000
-20.63%
|
$60,000
$6.88 P/Share
|
|
Jan 17
2026
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,665
-4.34%
|
$135,990
$6.78 P/Share
|
|
Jan 16
2026
|
Joseph Todisco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,585
+5.37%
|
$88,755
$3.38 P/Share
|
|
Jan 12
2026
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,417
-3.42%
|
$121,919
$7.15 P/Share
|
|
Jan 12
2026
|
Elizabeth Masson Hurlburt Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,794
-3.49%
|
$40,558
$7.15 P/Share
|
|
Jan 12
2026
|
Steven W Lefkowitz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+13.57%
|
$75,000
$5.63 P/Share
|
|
Jan 08
2026
|
Michael David Seckler Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133,156
+50.0%
|
-
|
|
Jan 02
2026
|
Kaufman Beth Zelnick Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,333
-6.28%
|
$135,996
$12.16 P/Share
|
|
Jan 02
2026
|
Elizabeth Masson Hurlburt Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,895
-6.16%
|
$130,740
$12.16 P/Share
|
|
Dec 30
2025
|
Alan W Dunton Director |
SELL
Open market or private sale
|
Direct |
20,000
-33.2%
|
$260,000
$13.0 P/Share
|
|
Dec 30
2025
|
Alan W Dunton Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+24.92%
|
$80,000
$4.03 P/Share
|
|
Dec 18
2025
|
Joseph Todisco Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-5.56%
|
$360,000
$12.0 P/Share
|
|
Dec 18
2025
|
Joseph Todisco Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+5.27%
|
$120,000
$4.43 P/Share
|
|
Dec 09
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
34,000
-41.23%
|
$408,000
$12.0 P/Share
|
|
Dec 09
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+18.68%
|
$238,000
$7.59 P/Share
|
|
Dec 09
2025
|
Steven W Lefkowitz Director |
SELL
Open market or private sale
|
Direct |
40,000
-33.2%
|
$440,000
$11.88 P/Share
|
|
Dec 02
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
46,657
-49.05%
|
$466,570
$10.0 P/Share
|
|
Dec 02
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,657
+16.76%
|
$186,628
$4.0 P/Share
|
|
Nov 24
2025
|
Janet Dillione Director |
SELL
Open market or private sale
|
Direct |
26,343
-35.21%
|
$237,087
$9.93 P/Share
|
|
Nov 24
2025
|
Janet Dillione Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,343
+9.22%
|
$79,029
$3.72 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 458K shares |
|---|---|
| Grant, award, or other acquisition | 342K shares |
| Open market or private purchase | 25K shares |
| Open market or private sale | 401K shares |
|---|---|
| Payment of exercise price or tax liability | 89.3K shares |